LIVRQNac (AXA 1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D

被引：0

|

作者：

Baum, Seth

Harrison, Stephen A.

Gunn, Nadege T.

Younes, Ziad

Kohli, Anita

Patil, Rashmee

Frias, Juan P.

Hamill, Michael

Daou, Nadine

Zhao, Jeff

Chakravarthy, Manu

Koziel, Margaret

机构：

来源：

DIABETES | 2021年 / 70卷

关键词：

D O I：

10.2337/db21-752-P

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

752-P

引用

收藏

页数：4

相关论文

共 44 条

[41] Patient Reported Outcomes (PRO) in a Study of Human Regular U-500 Insulin (U-500R) Delivered by Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections (MDI) in Patients with T2D
Peng, Xiaomei
Chen, Jieling
Fan, Ludi
Ilag, Liza
Ly, Trang T.
Johnson, Jennal
DIABETES, 2018, 67
[42] Impact of BMI on A1c Reduction in Response to IDegLira in Subjects with Type 2 Diabetes (T2D) Uncontrolled on SU, GLP-1RA, or Insulin Glargine: Analyses from Completed Phase 3b Trials
Harris, Stewart B.
Jaeckel, Elmar
Jodar, Esteban
Lingvay, Ildiko
Chandarana, Keval
Abrahamsen, Trine J.
Sorli, Christopher H.
DIABETES, 2016, 65 : A242 - A242
[43] Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D-The VIVID Study, Primary Population
Grunberger, George
Bhargava, Anuj
Ly, Trang T.
Zisser, Howard
Ilag, Liza
Malone, James K.
Zhang, Shuyu
Johnson, Jennal
DIABETES, 2018, 67
[44] Taspoglutide, a Once-Weekly Human GLP-1 Analog, Provides Comparable Glycemic Control to Insulin Glargine,' with Superior Weight Loss and Less Hypoglycemia in Type 2 Diabetes (T2D): A Phase 3, Open-Label Trial (T-emerge 5)
Nauck, Michael
Horton, Edward
Andjelkovic, Mirjana
Javier Ampudia-Blasco, F.
Boldrin, Mark N.
Balena, Raffaella
DIABETES, 2010, 59 : A16 - A16

← 1 2 3 4 5 →